Multiple Sclerosis

A retrospective study by Houtchens et al on annual pregnancy rates from 2006 to 2014 reveals that US women with multiple sclerosis (MS) had increased pregnancy rates as compared to women without MS.

Here are the top 5 articles for the month of September.

In a review of sex hormones and their role in the development of multiple sclerosis (MS), Ysrraelit and Correale compiled multiple references to provide clinical details regarding hormones and their respective immunological mechanisms.

For patients with multiple sclerosis (MS) being treated with natalizumab, cognitive function improved from baseline to 1 year and improved significantly across all domains from baseline to 2 years.

Noting a disconnect between evidence of benefit and uptake of exercise in patients with multiple sclerosis (MS), researchers offer behavioral science, specifically Social Cognitive Theory, as an approach to increasing participation.

The Multiple Sclerosis-Secondary Progressive Multi-Arm Randomization Trial (MS-SMART) is the first multiarm trial designed specifically to address the unmet need for further identification of neuroprotective drugs in secondary progressive multiple sclerosis.

A recent study has discovered that B cells mediate spontaneous T cell proliferation through the HLA-DR15 haplotype, and this interaction between T cells and B cells may serve as a key factor in understanding the pathogenesis of multiple sclerosis (MS).

As levels of disability increased among patients with multiple sclerosis (MS), cost of illness increased and health-related quality of life decreased.

Findings from a retrospective study comparing typical and myelocortical multiple sclerosis (MS) identified major pathological differences between the 2 MS subtypes and determined that demyelination and neuronal degeneration are independent processes.

New study findings have identified a subtype of multiple sclerosis—myelocortical multiple sclerosis—that has neuronal loss but no demyelination of the brain’s white matter, indicating that demyelination and neuronal degeneration occur independently.

Researchers evaluating the different methods used to predict the progression of multiple sclerosis (MS) found that human–machine hybrid predictions led to better prognoses than did machine learning algorithms or groups of humans alone.

A study has shed new light into the role of extracellular vesicles (EVs) in multiple sclerosis (MS) and how fingolimod, an immunomodulator drug, affects EVs.

More than half of patients with multiple sclerosis (MS) in the BETASLEEP study indicated poor sleep quality, which was linked to fatigue and reduced quality of life over time.

Researchers recently developed a systematic map of the cell types that make up the mouse nervous system which has the ability to reveal new information about the origin of neurological diseases, and may lead to a detailed map of the human brain.

Results from a long-term observational study found that disease-modifying therapies lowered conversion rates to secondary progressive multiple sclerosis (MS) among patients with relapsing-remitting multiple sclerosis.

A recent study found that the association between vitamin D (Vit D) status and multiple sclerosis (MS) susceptibility is genotype dependent and suggested that the outcome of Vit D status in MS is determined by gene-by-sex interactions.

A study recently published in Brain and Behavior has shown that certain magnetic resonance imaging (MRI) parameters correlated with a greater risk of recurrence and progression to multiple sclerosis (MS) within the first year following diagnosis of clinically isolated syndrome (CIS).

A recent study aimed to evaluate the burden of age of onset of cardiovascular conditions in a US population with multiple sclerosis, neuromyelitis optica spectrum disorder, or transverse myelitis and found that cardiovascular conditions are as common in those with demyelinating diseases compared with unaffected individuals.

A phase 1 trial evaluating the safety and tolerability of PRN2246, a Bruton's tyrosine kinase inhibitor, found the drug having no serious medication-related adverse events in healthy volunteers while also being able to reach the brain.

A recent study analyzed the role of purinergic receptor P2X4 in microglia/macrophages during autoimmune inflammation, finding that P2X4 receptors modulate microglia/macrophage inflammatory responses and identify allosteric modulator ivermectin (IVM) as a potential candidate to promote the repair of myelin damage.

Current therapy management mainly comprises of attempting to delay disease progression in neurodegenerative diseases but have been unable to reverse the myelin damage already done.

Multiple sclerosis (MS) involves the progressive loss of the protective layer of nerve fibers, myelin, and its loss, called demyelination, results in symptoms of MS. Blocking the protein receptor, muscarinic type 3 (M3R), may be effective in promoting remyelination in patients with MS, based on the results of a study published by the Journal of Neuroscience.

A study published in the journal Radiology has found that lower susceptibility in the thalamic and higher susceptibility in the basal ganglia, measured using quantitative susceptibility mapping, was associated with patients with MS and MS disease progression.

A recent study published in Radiology found that evaluating the differences in iron accumulation in the deep gray matter of the brain using a magnetic resonance imaging (MRI) technique may help to identify patients with multiple sclerosis (MS) that are at greater risk for disease progression and disability.

A recent study published in the European Journal of Clinical Nutrition found that healthcare professionals are downplaying the importance of patients with multiple sclerosis (MS) following national dietary guidelines.